HLA-A*0201 & B2M & HBV (FLLTKILTI) Produktliste
You Have Viewed 0 Of 0 Results
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Ajulemic acid | HU-239; CPL-7075; CT-3; JBT-101; DMH-THC-11-OIC; DMH-11C; IP-751 | Phase 3 Clinical | Corbus Pharmaceuticals Holdings Inc | Cystic Fibrosis; Lupus Vulgaris; Dermatomyositis; Lupus Erythematosus, Systemic; Scleroderma, Diffuse | Details |
| Dronabinol(AXIM Biotechnologies) | Phase 3 Clinical | Axim Biotech | Neoplasms; Child Nutrition Disorders; Vomiting; Nausea; Cachexia; Sarcopenia; Anorexia Nervosa | Details | |
| Dronabinol（Vertanical） | VER-01 | Phase 3 Clinical | Vertanical GmbH | Low Back Pain | Details |
| cannabidiol (Cardiol Therapeutics) | Phase 3 Clinical | Cardiol Therapeutics Inc | Coronavirus Disease 2019 (COVID-19); Pericarditis; Cardiovascular Diseases; Myocarditis | Details | |
| RG-7774 | RG-7774 | Phase 2 Clinical | F. Hoffmann-La Roche Ag | Diabetic Retinopathy | Details |
| ART-2713 | NEO-1940; ART-2713; ART27.13; AZD-1940 | Phase 2 Clinical | Astrazeneca Plc, Neomed Inc, Pfizer Inc | Weight Loss; Pain; Anorexia; Cachexia; Low Back Pain | Details |
| Cannabidiol/hydroxychloroquine | IHL-675A; IHL-675 | Phase 2 Clinical | Incannex Healthcare Ltd | Arthritis, Rheumatoid; Respiratory Distress Syndrome, Adult | Details |
| Beta-Caryophyllene | Phase 2 Clinical | Hartford Hospital | Pain | Details | |
| CNTX-6016 | CNTX-6016 | Phase 1 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Pain; Chronic Pain; Diabetic Neuropathies; Nociceptive Pain | Details |
| ZYN-001 | ZYN-001 | Phase 1 Clinical | Zynerba Pharmaceuticals | Neuralgia; Fibromyalgia | Details |
| EHP-101 | EHP-101; VCE-004; VCE-004.8 | Phase 1 Clinical | Emerald, Vivacell Biotechnology | Multiple Sclerosis, Relapsing-Remitting; Scleroderma, Diffuse | Details |
| IPI 201（Isosceles Pharmaceuticals Inc ） | IPI-201 | Phase 1 Clinical | Pain, Postoperative | Details | |
| HU-308 | PPP-003 | Phase 1 Clinical | Panag Pharma | Pain; Retinal Diseases; Uveitis; Xerophthalmia; Ocular inflammation | Details |
| NTRX-07 | MDA7; NTRX-07; MDA-7 | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center | Alzheimer Disease; Neuralgia | Details |
| MP-10X | MP-10X | Clinical | Medipure Holdings | Pain | Details |
| Cannabidiol/Palmitoylethanolamide | THX-210; SCI–210 | Clinical | Therapix Biosciences Ltd | Autism Spectrum Disorder; Diabetic Neuropathies | Details |
| C20T5 | C20T5 | Murdoch Childrens Research Institute | Details | ||
| C12T12 | C12T12 | Murdoch Childrens Research Institute | Details |
Inverkehr gebrachte Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Frühestes Markenname | Frühestes Genehmigungsland | Früheste Indikation | Früheste Genehmigungsgesellschaft | Früheste Genehmigungsdatum | Indikationen | Klinische Studie |
|---|---|---|---|---|---|---|---|---|---|---|
| Cannabidiol/Dronabinol | THC-5; delta-9-THC/CBD; MPL-001; MPL-005; GW-1000; KL16-012; BOL-DP-o-04; GW-1000-02; PPP-001; MGC-ODT | Approved | Gw Pharmaceuticals | Sativex, Qixleef | Canada | Muscle Spasticity; Neuralgia; Cancer Pain; Chronic Pain; Multiple Sclerosis | null | 2005-04-01 | Back Pain; Phobia, Social; Neuralgia, Postherpetic; Huntington Disease; Reflex Sympathetic Dystrophy; Tourette Syndrome; Muscle Spasticity; Malnutrition; Sciatica; Acute Pain; Neuromyelitis Optica; Arthritis, Psoriatic; Neuralgia; Dementia; Panic Disorder; Osteoarthritis, Knee; Hepatic Insufficiency; Stress Disorders, Post-Traumatic; Healthy Aging; Hidradenitis Suppurativa; Agoraphobia; Drug Resistant Epilepsy; Renal Insufficiency, Chronic; Social Behavior; Corticobasal degeneration; Cerebral Palsy; Low Back Pain; Neoplasms; Sleep Initiation and Maintenance Disorders; Peripheral Nervous System Diseases; Pain; Chronic Pain; Depression; Depressive Disorder, Major; Marijuana Abuse; Marijuana Use; Spasm; Squamous Cell Carcinoma of Head and Neck; Cancer Pain; Renal Insufficiency; Spinal Cord Injuries; Migraine Disorders; Arthritis, Rheumatoid; Neck Pain; Diabetic Neuropathies; Sleep Wake Disorders; Opioid-Related Disorders; Essential Tremor; Anorexia; Anxiety Disorders; Kidney Diseases; Multiple Sclerosis; Tic Dis | Details |
| Cannabidiol | AVCN-583601; GLA-015; BTX-1503; BTX-1801; BTX-1702; LYT-310; RAD011; PBX-1308; RAD-011; BRCX-014; RLS-103; GWP-42003; GWP-42003-P; BOL-DP-o-05; GW-42003; BTX-1204; ZYN-002; PTL-101; CHI-902; APH-1501 | Approved | Gw Pharmaceuticals Plc | Epidiolex, Epidyolex, Zygel, Cannepil | United States | Epilepsies, Myoclonic; Lennox Gastaut Syndrome | null | 2018-06-25 | Migraine Disorders; Peripheral Nervous System Diseases; Acne Vulgaris; HIV Infections; Tobacco Smoking; Ovarian Neoplasms; Sleep Initiation and Maintenance Disorders; Facial Pain; Substance-Related Disorders; Marijuana Smoking; Tobacco Use Cessation; Anxiety; Pain; Chronic Pain; Marijuana Use; Seizures; Tuberous Sclerosis; Rett Syndrome; Schizophrenia; Appetitive Behavior; Autism Spectrum Disorder; Marijuana Abuse; Brain Injuries, Traumatic; Depression; Alcoholic Intoxication; Inflammatory Bowel Diseases; Fatty Liver; Child Behavior Disorders; Diabetes Mellitus, Type 2; Spinal Cord Injuries; Sleep Wake Disorders; Anxiety Disorders; Neoplasms; Opioid-Related Disorders; Diabetic Neuropathies; Coronavirus Disease 2019 (COVID-19); Musculoskeletal Pain; Graft vs Host Disease; Blepharospasm; Dyspepsia; Arthritis, Rheumatoid; Psychotic Disorders; Hyperalgesia; Chronic Urticaria; Hoarding Disorder; Bipolar Disorder; Pancreatic Neoplasms; Brain Diseases; Dysmenorrhea; Sturge-Weber Syndrome; Lennox Gastaut Syndrome; Ph | Details |